The incidence rates of diarrhea and neutropenia are significantly higher, while median OS tends to be shorter in metastatic colorectal cancer patients receiving irinotecan with UGT1A1*28 heterozygous or homozygous mutations compared to the wild-type allele [17]. This evidence concerns the gene UGT1A1 and Decreased total neutrophil count.